Mary Ann Gray


Mary Ann Gray, Ph.D. was elected to our Board in December 2018. Dr. Gray also serves as a member of the Compensation and Nominating and Corporate Governance Committees of the company’s Board.

Dr. Gray has extensive experience in the biotechnology and biopharmaceutical industry and most recently served on the boards of: Senomyx and Juniper Pharmaceuticals, a women’s health company, prior to the acquisition of both companies; TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases; Dyax, a rare disease company acquired by Shire in 2016; and ACADIA Pharmaceuticals, focused on commercialization of CNS therapies. She is President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm.

Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes and beginning her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager. She holds a Bachelor of Science degree from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.